nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

24.01.2018 | Original Paper

Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis

verfasst von: Marc Krause, Yikang Zhu, Maximilian Huhn, Johannes Schneider-Thoma, Irene Bighelli, Adriani Nikolakopoulou, Stefan Leucht

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Negative symptoms are the core of schizophrenia, but whether antipsychotics are efficacious for their treatment is unclear. Moreover, there is debate whether patients in relevant trials should have predominant negative symptoms or whether prominent negative symptoms are also acceptable.

Methods

We systematically reviewed randomised, blinded antipsychotic drug trials in patients with schizophrenia and either predominant or prominent negative symptoms (last search Dec 12, 2017). Separate pairwise meta-analyses were conducted in these two populations. The primary outcome was negative symptoms. Depressive, symptoms, positive symptoms, and extrapyramidal side-effects were analysed as causes of secondary negative symptoms.

Findings

We included 21 randomized-controlled trials with 3451 participants which revealed the following significant differences in the primary outcome: in patients with predominant negative symptoms amisulpride was superior to placebo (N = 4; n = 590, SMD 0.47, CI 0.23, 0.71), olanzapine was superior to haloperidol in a small trial (n = 35) and cariprazine outperformed risperidone (N = 1, n = 456, SMD − 0.29, CI − 0.48, − 0.11). In patients with prominent negative symptoms, olanzapine and quetiapine were superior to risperidone in single trials. Overall, studies in prominent negative symptoms were potentially more confounded by improvements of secondary negative symptoms.

Interpretation

Amisulpride is the only antipsychotic that outperformed placebo in the treatment of predominant negative symptoms, but there was a parallel reduction of depression. Cariprazine was better than risperidone in a large trial that was well-controlled for secondary negative symptoms, but the trial was sponsored by its manufacturer. Future trials should apply scientifically developed definitions such as the deficit syndrome and the persistent negative symptoms concept.

Nur mit Berechtigung zugänglich

Buchanan RW, Kirkpatrick B, Heinrichs DW et al (1990) Clinical correlates of the deficit syndrome of schizophrenia. Am J Psychiatry 147(3):290–294. https://doi.org/10.1176/ajp.147.3.290 CrossRefPubMed

Carpenter WT, Heinrichs JR, Wagman DW AM (1988) Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 145(5):578–583. https://doi.org/10.1176/ajp.145.5.578 CrossRefPubMed

Crow TJ (1985) the two-syndrome concept: origins and current status. Schizophr Bull 11(3):471–488. https://doi.org/10.1093/schbul/11.3.471 CrossRefPubMed

Strauss JS, Carpenter WT, Bartko JR JJ (1974) The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull 11:61–69CrossRef

Andreasen NC, Olsen S (1982) Negative v positive schizophrenia. Definition and validation. Arch General Psychiatry 39(7):789–794CrossRef

Marder SR, Galderisi S (2017) The current conceptualization of negative symptoms in schizophrenia. World Psychiatry 16(1):14–24. https://doi.org/10.1002/wps.20385 CrossRefPubMedPubMedCentral

Buchanan RW (2007) Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull 33(4):1013–1022. https://doi.org/10.1093/schbul/sbl057 CrossRefPubMed

Leucht S, Leucht C, Huhn M et al. (2017) Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review; bayesian meta-analysis; and meta-regression of efficacy predictors. Am J Psychiatry. https://doi.org/10.1176/appi.ajp.2017.16121358

Leucht S, Arbter D, Engel RR et al (2009) How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14(4):429–447. https://doi.org/10.1038/sj.mp.4002136 CrossRefPubMed

10.

Leucht S, Corves C, Arbter D, Engel R, Li C, Davis J (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia. A meta-analysis. Lancet 373:31–41. https://doi.org/10.1016/S0140-6736(08)61764-X

11.

Marder SR, Alphs L, Anghelescu I-G et al (2013) Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophr Res 150(2–3):328–333. https://doi.org/10.1016/j.schres.2013.07.058 CrossRefPubMed

12.

Leucht S, Huhn M, Rothe P et al (2016) Which are the most important first-generation antipsychotic drugs? Survey of international schizophrenia experts. Abstracts from the 5th Biennial SIRS Conference—Poster Abstracts. NPJ schizophrenia, p 25

13.

Leucht S, Pitschel-Walz G, Engel RR et al (2002) Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 159(2):180–190. https://doi.org/10.1176/appi.ajp.159.2.180 CrossRefPubMed

14.

Fusar-Poli P, Papanastasiou E, Stahl D et al (2015) Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull 41(4):892–899. https://doi.org/10.1093/schbul/sbu170 CrossRefPubMed

15.

Remington G, Foussias G, Fervaha G et al (2016) Treating negative symptoms in schizophrenia: an update. Curr Treat Options Psychiatry 3:133–150. https://doi.org/10.1007/s40501-016-0075-8 CrossRefPubMedPubMedCentral

16.

Elbourne DR, Altman DG, Higgins JPT et al (2002) Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 31(1):140–149CrossRefPubMed

17.

Divine GW, Brown JT, Frazier LM (1992) The unit of analysis error in studies about physicians’ patient care behavior. J General Intern Med 7(6):623–629CrossRef

18.

Higgins JPTea (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. Wiley and Sons, Chichester

19.

Bian ZX, Li YP, Moher D et al. (2006) Improving the quality of randomized controlled trials in Chinese herbal medicine, part I: clinical trial design and methodology. Zhong xi yi jie he xue bao J Chin Integr Med 4(2):120–129CrossRef

20.

Wu T, Li Y, Bian Z et al (2009) Randomized trials published in some Chinese journals: how many are randomized? Trials 10:46. https://doi.org/10.1186/1745-6215-10-46 CrossRefPubMedPubMedCentral

21.

Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261–276CrossRefPubMed

22.

Andreasen NC (1989) The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl 155(7):49–58

23.

Kirkpatrick B, Buchanan RW, McKenny PD et al (1989) The schedule for the deficit syndrome. An instrument for research in schizophrenia. Psychiatry Res 30(2):119–123. https://doi.org/10.1016/0165-1781(89)90153-4 CrossRefPubMed

24.

Leucht S, Cipriani A, Spineli L et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia. A multiple-treatments meta-analysis. Lancet 382(9896):951–962CrossRefPubMed

25.

Furukawa TA, Barbui C, Cipriani A et al (2006) Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol 59(1):7–10. https://doi.org/10.1016/j.jclinepi.2005.06.006 CrossRefPubMed

26.

Higgins JPT, Jackson D, Barrett JK et al (2012) Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3(2):98–110. https://doi.org/10.1002/jrsm.1044 CrossRefPubMedPubMedCentral

27.

White IR, Barrett JK, Jackson D et al (2012) Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods 3(2):111–125. https://doi.org/10.1002/jrsm.1045 CrossRefPubMedPubMedCentral

28.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188. https://doi.org/10.1016/0197-2456(86)90046-2 CrossRefPubMed

29.

Chaimani A, Salanti G (2015) Visualizing assumptions and results in network meta-analysis: the network graphs package. Stata Journal 15(4):905–950

30.

Review Manager (RevMan) (2014) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration

31.

Boyer P, Lecrubier Y, Puech AJ et al (1995) Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166(1):68–72CrossRefPubMed

32.

Buchanan RW, Panagides J, Zhao J et al (2012) Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol 32(1):36–45. https://doi.org/10.1097/JCP.0b013e31823f880a CrossRefPubMed

33.

Danion JM, Rein W, Fleurot O (1999) Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry 156(4):610–616PubMed

34.

Lecrubier Y, Quintin P, Bouhassira M et al (2006) The treatment of negative symptoms and deficit states of chronic schizophrenia. olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatr Scand 114(5):319–327CrossRefPubMed

35.

Lindenmayer JP, Khan A, Iskander A et al (2007) A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry 68(3):368–379CrossRefPubMed

36.

Loo H, Poirier-Littre MF, Theron M et al (1997) Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 170:18–22CrossRefPubMed

37.

Moller HJ, Riedel M, Muller N et al (2004) Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms. a randomized double-blind multicenter trial. Pharmacopsychiatry 37(6):270–278CrossRefPubMed

38.

Németh G, Laszlovszky I, Czobor P et al (2017) Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia. A randomised, double-blind, controlled trial. Lancet 389(10074):1103–1113. https://doi.org/10.1016/S0140-6736(17)30060-0 CrossRefPubMed

39.

Alvarez E, Ciudad A, Olivares JM et al (2006) A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia. J Clin Psychopharmacol 26(3):238–249CrossRefPubMed

40.

Barnas C, Stuppack CH, Miller C et al (1992) Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidol. Int Clin Psychopharmacol 7(1):23–27CrossRefPubMed

41.

Buchanan RW, Breier A, Kirkpatrick B et al (1998) Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 155(6):751–760. https://doi.org/10.1176/ajp.155.6.751 PubMedCrossRef

42.

Kinon BJ, Noordsy DL, Liu-Seifert H et al (2006) Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.[Erratum appears in J Clin Psychopharmacol 26(5) 2009 Apr. 169]. J Clin Psychopharmacol 29(2):453–461CrossRef

43.

Pichot P, Boyer P (1989) Controlled double blind multi-centre trial of low dose amisulpride versus fluphenazine in the treatment of the negative syndrome of chronic schizophrenia expansion. Scientifique Francaise 125–137

44.

Riedel M, Muller N, Strassnig M et al (2005) Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci 255(6):432–437CrossRefPubMed

45.

Ruhrmann S, Kissling W, Lesch OM et al (2007) Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms. Prog Neuropsychopharmacol Biol Psychiatry 31(5):1012–1022CrossRefPubMed

46.

Saletu B, Kufferle B, Grunberger J et al (1994) Clinical, EEG mapping and psychometric studies in negative schizophrenia. comparative trials with amisulpride and fluphenazine. Neuropsychobiology 29(3):125–135CrossRefPubMed

47.

Sirota P, Pannet I, Koren A et al (2006) Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia. Human 21(4):227–234

48.

Speller JC, Barnes TR, Curson DA et al (1997) One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. Br J Psychiatry 171:564–568CrossRefPubMed

49.

Olie JP, Spina E, Murray S et al (2006) Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia. results of a 12-week, double-blind study. Int Clin Psychopharmacol 21(3):143–151CrossRefPubMed

50.

Soni SD, Mallik A, Schiff AA (1990) Sulpiride in negative schizophrenia. A placebo-controlled double-blind assessment. Hum Psychopharmacol 5(3):233–238CrossRef

51.

Asada S, Ishimaru T, Kubo S et al (1976) A double-blind study of sulpiride and perphenazine in 82 schizophrenics. Encephale 2(1):73–83PubMed

52.

Cesarec Z, Eberhard G, Nordgren L (1974) A controlled study of the antipsychotic and sedative effects of neuroleptic drugs and amphetamine in chronic schizophrenics. A clinical and experimental-psychological study. Acta Psychiatr Scand Suppl 249:65–77CrossRefPubMed

53.

Paillere-Martinot ML, Lecrubier Y, Martinot JL et al (1995) Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 152(1):130–134CrossRefPubMed

54.

Collins AD, Dundas J (1967) A double-blind trial of amitriptyline/perphenazine, perphenazine and placebo in chronic withdrawn inert schizophrenics. Br J Psychiatry 113(505):1425–1429CrossRefPubMed

55.

Abbas AI, Hedlund PB, Huang X-P et al (2009) Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology 205(1):119–128. https://doi.org/10.1007/s00213-009-1521-8 CrossRefPubMedPubMedCentral

56.

Boyer P, Lecrubier Y, Stalla-Bourdillon A et al (1999) Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology 39(1):25–32CrossRefPubMed

57.

Kiss B, Horváth A, Némethy Z et al (2010) Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 333(1):328–340. https://doi.org/10.1124/jpet.109.160432 CrossRefPubMed

58.

Jensen NH, Rodriguiz RM, Caron MG et al (2008) N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology 33(10):2303–2312. https://doi.org/10.1038/sj.npp.1301646 CrossRefPubMed

59.

Zohar J, Nutt DJ, Kupfer DJ et al (2014) A proposal for an updated neuropsychopharmacological nomenclature. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 24(7):1005–1014. https://doi.org/10.1016/j.euroneuro.2013.08.004 CrossRef

60.

Sagud M, Mihaljevic-Peles A, Begic D et al (2011) Antipsychotics as antidepressants: what is the mechanism? Psychiatr Danub 23(3):302–307PubMed

61.

Correll CU, Rubio JM, Inczedy-Farkas G et al (2017) Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 74(7):675–684. https://doi.org/10.1001/jamapsychiatry.2017.0624 CrossRefPubMed

62.

Helfer B, Samara MT, Huhn M et al (2016) Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry 173(9):876–886. https://doi.org/10.1176/appi.ajp.2016.15081035 CrossRefPubMed

63.

Mao Y-M, Zhang M-D (2015) Augmentation with antidepressants in schizophrenia treatment: benefit or risk. Neuropsychiatr Dis Treat 11:701–713. https://doi.org/10.2147/NDT.S62266 PubMedPubMedCentralCrossRef

64.

Cazorla P, Panagides J, Zhao J et al (2010) Long-term efficacy of asenapine in people with persistent negative symptoms of schizophrenia. Int J Neuropsychopharmcol 13:215. https://doi.org/10.1017/S1461145710000635 CrossRef

65.

Kirkpatrick B, Fenton WS, Carpenter WT et al (2006) The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 32(2):214–219. https://doi.org/10.1093/schbul/sbj053 CrossRefPubMedPubMedCentral

66.

Levine SZ, Leucht S (2013) Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms. Schizophr Res 145(1–3):125–127. https://doi.org/10.1016/j.schres.2012.12.032 CrossRefPubMed

67.

Mucci A, Merlotti E, Üçok A et al (2017) Primary and persistent negative symptoms: concepts, assessments and neurobiological bases. Schizophr Res 186:19–28. https://doi.org/10.1016/j.schres.2016.05.014 CrossRefPubMed

Titel: Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis
verfasst von: Marc Krause
Yikang Zhu
Maximilian Huhn
Johannes Schneider-Thoma
Irene Bighelli
Adriani Nikolakopoulou
Stefan Leucht
Publikationsdatum: 24.01.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 7/2018
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-018-0869-3

Neu im Fachgebiet Psychiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis